Economic Atlas
Companies/Kyntra Bio, Inc.
Company profile

Kyntra Bio, Inc.

NASDAQ: KYNB · Healthcare · Biotechnology
PublicHQ San Francisco, CA · San FranciscoCIK 0000921299Reports USD
#681 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
60C
Revenue TTM
$7.4M
Rev growth YoY (TTM)
-110.2%
Net income (FY)
$183.5M
Employees
34
as of 2026-08-20
Market cap
$28.9M
as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$6.4M$6.4M2025
Net income$183.5M$183.5M2025
Operating income-$45.9M-$45.9M2025
Total assets$119.6M$119.6M2025
Liabilities$115.1M$115.1M2025
Equity-$30.0M-$30.0M2025

Revenue trend

FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
Drug Product Revenue100%
By geography
Europe88%
JAPAN12%
The read

What is Kyntra Bio, Inc.’s revenue?

Kyntra Bio, Inc. booked $6.4M in FY2025 revenue, contracting 78% year over year — slower than 88% of Healthcare companies we track, at a 2848.6% net margin.

Peers · Healthcare
Evommune, Inc.46DEncision Inc.——GlobeImmune, Inc.——Viveve Medical, Inc.——Korro Bio, Inc.41DHTG Molecular Diagnostics, Inc.——
Neighbors
San Francisco →
Visa Inc.$40.0B86AWells Fargo & Company$85.1B55CSalesforce, Inc.$41.5B80B+Uber Technologies, Inc.$52.0B71BPrologis, Inc.$8.8B66BCloudflare, Inc.$2.2B59C
Key facts
CEOThane Wettig
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Francisco, CA
ExchangeNASDAQ: KYNB
Employees34
IPO date2014-11-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.